Shuttle Pharmaceuticals Holdings, Inc. Logo

Shuttle Pharmaceuticals Holdings, Inc.

Develops drugs to enhance radiation therapy for cancer and offers predictive diagnostics.

SHPH | US

Overview

Corporate Details

ISIN(s):
US8256933024
LEI:
Country:
United States of America
Address:
401 PROFESSIONAL DRIVE, 20879 GAITHERSBURG
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company dedicated to improving outcomes for cancer patients by enhancing the effectiveness of radiation therapy (RT). The company develops novel therapies designed to sensitize cancer cells to radiation while protecting healthy tissues. Its lead product candidate, Ropidoxuridine, is a Phase II clinical-stage oral radiation sensitizer. The development pipeline also includes a portfolio of pre-clinical selective histone deacetylase (HDAC) inhibitors. In addition to therapeutics, Shuttle Pharma is developing diagnostic technologies, such as predictive blood tests for prostate cancer patients, to inform therapeutic decision-making and patient management. The company utilizes a proprietary drug discovery platform and strategic collaborations to advance its mission of increasing cancer cure rates and improving patient quality of life.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Shuttle Pharmaceuticals Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shuttle Pharmaceuticals Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Shuttle Pharmaceuticals Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Whitehawk Therapeutics, Inc. Logo
Develops advanced antibody-drug conjugates (ADCs) for difficult-to-treat cancers.
United States of America
WHWK
WooGeneB&GCO.,Ltd Logo
Manufactures veterinary medicines, vaccines, and supplements for livestock and aquatic animals.
South Korea
018620
X4 Pharmaceuticals, Inc Logo
Developing and commercializing novel therapies for rare diseases of the immune system.
United States of America
XFOR
XBiotech Inc. Logo
Develops therapeutic antibodies from natural human immunity for inflammatory diseases and oncology.
United States of America
XBIT
Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden
XBRANE
Xencor Inc Logo
Engineering antibody & cytokine therapeutics for cancer and autoimmune diseases via its XmAb platform.
United States of America
XNCR
Xenon Pharmaceuticals Inc. Logo
A neuroscience biopharma developing novel therapeutics for epilepsy and depression.
United States of America
XENE
Xeris Biopharma Holdings, Inc. Logo
Develops ready-to-use injectable drugs for chronic, metabolic, and rare diseases.
United States of America
XERS
Xintela AB Logo
Develops stem cell therapies for osteoarthritis and venous leg ulcers using proprietary technology.
Sweden
XINT
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY

Talk to a Data Expert

Have a question? We'll get back to you promptly.